复方阿司匹林抑制心血管病患者血小板聚集的24周疗效

摘要

Objective: To evaluate the inhibition of platelet aggregation after 24-week therapy of compound aspirin( dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin) in cardiovascular patients.Methods: A total of 103 cardiovascular patients with high platelet aggregation rate were enrolled, who needed the treatment of aspirin.They were treated with oral doses of dihydroxyaluminum aminoacetate-heavy magnesium carbonateaspirin( contain 162 mg aspirin) daily for 24 weeks.Platelet aggregation was measured before and 6, 12, 24 weeks after administration.Results: The platelet aggregation was significantly inhibited 6, 12 and 24 weeks after administration.There were significant differences in the platelet aggregation between baseline and post-treatment.The inhibition rate of platelet aggregation at 6, 12, 24 weeks after administration were - (20.49 ±22.35 )％,-(28.10 ±22.88)％, and -(23.23 ± 22.68 )％, respectively.The platelet aggregation was inhibited at 12 weeks more than at 6 weeks follow-up, but less at 24 weeks than at 12 weeks follow-up(P ＜0.05).Conclusion:The inhibitive effect of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablet on platelet aggregation is conclusive; however, this effect is lower at 24 weeks than at 12 weeks.%目的:观察24周疗程中复方阿司匹林(铝镁匹林)抑制心血管病患者血小板聚集功能的效果变化.方法:选择临床需要服用阿司匹林抗血小板治疗且ADP诱导的血小板聚集率增高的心血管病患者103例,给予铝镁匹林2片(含阿司匹林162 mg)口服24周.于用药前及用药6,12,24周后分别测定血小板聚集率.结果:服用铝镁匹林后患者的血小板聚集率显著降低,6,12,24周测定血小板聚集率与基线比较有极显著差异,血小板聚集抑制率分别为-(20.49±22.35)%,-(28.10 ±22.88)%,-(23.23±22.68)%.12周的血小板聚集率较6周进一步下降,但24周较12周则明显升高,两个差值均有统计学差异(P<0.05).结论:铝镁匹林可明显降低患者的血小板聚集功能,但抗血小板聚集作用在24周后较12周有明显下降.